Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
An unmasked AGA does not
The clinically relevant reductions in weight and SBP along with proven CV benefits in the SUSTAIN 6 trial support its preferred use in persons with established CV disease
In March 2024, Wegovy was also approved to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular (heart, blood vessel) disease and either obesity or overweight
Do not wait for your next review call your treating doctor, or in an emergency dial 112
(For the Wegovy pill, the weight loss is a bit less, at 13.6% in 64 weeks.) A head-to-head randomized clinical trial, SURMOUNT-5 , tested Zepbound vs Wegovy in people with obesity
CertifiedTM: June 2025 - GLP-1s and Lean Mass: What the research shows
US$ 23.02
US$ 24.45
US$ 26.46
US$ 23.42
US$ 20.05
